BackCytRx Overview

CytRx Current Cash

Latest current cash for CYTR: $210M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$206.95M

Peer average

Loading

CytRx Current Cash History

Loading

CytRx vs. peers: Current Cash Comparison

Loading

CytRx Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

CytRx (CYTR) FAQ

CytRx's current cash stands at $210M as of March 2025. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Open the history chart to see whether CytRx's current cash is expanding or contracting. Sustained growth in current cash can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how CytRx's current cash evolved across reporting periods, while the comparison chart places CYTR next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, current cash is commonly used to spot outliers. CytRx's reading of $210M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.